Descriptive and prognostic value of a computational model of metastasis in high-risk neuroblastoma | medRxiv
Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study | Semantic Scholar
Full article: Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy
Topotecan-Vincristine-Doxorubicin in stage 4 high-Risk neuroblastoma patients failing to achieve a complete metastatic response to rapid COJEC: A SIOPEN study.
LEXIPatho: Neuroblastome
PDF) Rapid COJEC versus standard induction therapies for high-risk neuroblastoma (Protocol)
HIGH-RISK NEUROBLASTOMA: STANDARD CLINICAL PRACTICE RECOMMENDATIONS Moderation: Ruth Ladenstein
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial - The Lancet Oncology
Histiocytoses: emerging neoplasia behind inflammation - The Lancet Oncology
Management of neuroblastoma in limited-resource settings
Browse Preprints - Authorea
Cancers | Free Full-Text | Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1 - Transplantation and Cellular Therapy, Official Publication of the ...
Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue | Bone Marrow Transplantation
Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1. - Abstract - Europe PMC
Neuroblastoma - Chung - 2021 - Pediatric Blood & Cancer - Wiley Online Library
Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SI
Trial profile COJEC=cisplatin, carboplatin, cyclophosphamide,... | Download Scientific Diagram
Children | Free Full-Text | High-Risk Neuroblastoma Treatment Review
Clonal evolution during metastatic spread in high-risk neuroblastoma | bioRxiv
The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma - ScienceDirect
HIGH-RISK NEUROBLASTOMA: STANDARD CLINICAL PRACTICE RECOMMENDATIONS Moderation: Ruth Ladenstein
SOLUTION: Peinemann2016 - Studypool
Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study | Journal of Clinical Oncology
HIGH-RISK NEUROBLASTOMA: STANDARD CLINICAL PRACTICE RECOMMENDATIONS Moderation: Ruth Ladenstein
